# Study to Evaluate the Efficacy and Safety of Combination Aliskiren/Amlodipine in Patients With Hypertension Not Adequately Responding to Amlodipine Alone

> **NCT00778921** · PHASE3 · COMPLETED · sponsor: **Novartis** · enrollment: 847 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** Amlodipine 10 mg
- **DRUG:** Aliskiren 150
- **DRUG:** Amlodipine 300

## Key facts

- **NCT ID:** NCT00778921
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10
- **Primary completion:** 2009-06
- **Final completion:** 2009-06
- **Target enrollment:** 847 (ACTUAL)
- **Last updated:** 2016-10-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00778921

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00778921, "Study to Evaluate the Efficacy and Safety of Combination Aliskiren/Amlodipine in Patients With Hypertension Not Adequately Responding to Amlodipine Alone". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00778921. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*